Insider Buying: CalciMedica, Inc. (NASDAQ:CALC) CEO Acquires 20,000 Shares of Stock

CalciMedica, Inc. (NASDAQ:CALC) CEO A. Rachel Leheny acquired 20,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were purchased at an average cost of $3.75 per share, for a total transaction of $75,000.00. Following the completion of the acquisition, the chief executive officer now owns 130,926 shares in the company, valued at $490,972.50. This represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

A. Rachel Leheny also recently made the following trade(s):

• On Tuesday, August 27th, A. Rachel Leheny acquired 1,000 shares of CalciMedica stock. The stock was acquired at an average cost of $4.19 per share, with a total value of $4,190.00.

CalciMedica Stock Down 2.7 %

Shares of CalciMedica stock traded down $0.10 during trading on Friday, reaching $3.60. 174,089 shares of the stock were exchanged, compared to its average volume of 34,136. The firm has a market cap of $38.70 million, a price-to-earnings ratio of -2.57 and a beta of 1.27. CalciMedica, Inc. has a 1 year low of $2.14 and a 1 year high of $8.38. The stock’s fifty day moving average is $4.27 and its 200 day moving average is $4.64.

CalciMedica (NASDAQ:CALC) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. Equities analysts forecast that CalciMedica, Inc. will post -2.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on CALC shares. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of CalciMedica in a research note on Tuesday, August 13th. Oppenheimer increased their price objective on CalciMedica from $14.00 to $20.00 and gave the company an “outperform” rating in a research note on Wednesday, July 10th.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.